Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Rohini Sharma(Hammersmith Hospital)
Cited by 45
Related Papers
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
|JAMA Oncology|2019|582
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
|The Lancet Oncology|2023|184
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
|Clinical Cancer Research|2011|168
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
|Annals of Oncology|2022|100
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
|Journal of Thoracic Oncology|2023|91